EDITORIAL

Impact factor achieved (But this is just the beginning)

Factor de impacto logrado (Pero esto es solo el principio)

In November 2023, the *Journal of Senology and Breast Pathology* (Revista de Senología y Patología Mamaria) earned a place in the prestigious group of Web of Science® journals, a Clarivate Analytics Company. Consequently, articles published after 2021 will be included in the Emerging Sources Citation Index (ESCI).

To evaluate the journal, Web of Science’s expert editors employed a set of 28 criteria. These include 24 quality criteria for editorial rigor and best practices at the journal level, and 4 impact criteria to select the most impactful journals in their respective fields based on citation activity.

Journals meeting the quality criteria enter Emerging Sources Citation Index™ (ESCI), and those meeting additional impact criteria enter Science Citation Index Expanded™ (SCIE). Consequently, the *Journal of Senology and Breast Pathology* (Revista de Senología y Patología Mamaria) (ESCI) may be further evaluated and added to additional Clarivate™ products to meet the needs of the scientific and scholarly research community (SCIE).

The relationship between Web of Science, Journal Citation Reports, and Impact Factor

The Journal Citation Reports™ (JCR) is an annual publication by Clarivate, integrated into the Web of Science and accessible through the Web of Science Core Collection. It provides details on academic journals in natural and social sciences, including impact factors. It undergoes annual updates for relevance and accuracy. Journals accepted into SCIE or ESCI before January 1, remaining covered when JCR production starts in March, are eligible for the June release of JCR data and receive a Web of Science Journal Citation Indicator (JCI). Previously, only SCIE and SSCI journals meeting these requirements were eligible for a Journal Impact Factor™ (JIF). From the June 2023 JCR release, all journals meeting these requirements are eligible for a Journal Impact Factor™ (JIF).

Therefore, the *Journal of Senology and Breast Pathology* (Revista de Senología y Patología Mamaria) will be assigned an impact factor in the coming months.

Moving forward

While these are excellent news, it marks the beginning, not the end. The journey started years ago and has been challenging at every step.

It's fair to express gratitude to the editors, reviewers (both past and present), and especially the authors contributing high-quality works.

We are fortunate to have 3 crucial elements: an excellent editorial team, a high-caliber body of reviewers, and a large number of authors trusting the *Journal of Senology and Breast Pathology* (Revista de Senología y Patología Mamaria) for publishing their research.

However, we face significant challenges for the future. The *Journal of Senology and Breast Pathology* (Revista de Senología y Patología Mamaria) is no longer confined to being a local or regional journal; it has evolved into an international journal. Expansion is essential, but it's crucial not to lose sight of our roots as the voice of the Spanish Society of Senology and Breast Disease.

Maintaining high-quality articles is essential for increasing citations and improving the impact factor. The contribution of researchers and authors remains crucial.

Considering the reality of social media, the *Journal of Senology and Breast Pathology* must develop strategies for effective communication with the scientific community.

In summary, with the ongoing evolution and the awaited impact factor, the collaboration of everyone—editors, reviewers, and authors—is a necessary and fundamental part of future success. It's the only way for the *Journal of Senology and Breast Pathology* (Revista de Senología y Patología Mamaria) to achieve the position it deserves in the scientific world.

https://doi.org/10.1016/j.senol.2023.100561
0214-1582/© 2023 Published by Elsevier España, S.L.U. on behalf of SESPM.